Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 12 December 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Different intravenous iron formulations for anemia in IBD

A study in the latest issue of the Alimentary Pharmacology & Therapeutics compares the efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.

News image

Iron deficiency anemia is a common complication of inflammatory bowel disease (IBD) associated with reduced quality of life and increased hospitalization rates. 

While the best way of treating iron deficiency anemia in IBD patients is not clearly established, current European guidelines recommend intravenous iron therapy in IBD patients with severe anemia or intolerance to oral iron compounds.

Dr Stein and colleagues from Germany compared the efficacy and tolerability of different intravenous iron formulations used to treat iron deficiency anemia in IBD patients in a systematic review and Bayesian network meta-analysis.

In 2016, the researchers systematically searched for studies analysing efficacy and safety of intravenous iron for iron deficiency anemia therapy in IBD. 

Pooled data revealed adverse event rates of 12% for ferric carboxymaltose
Alimentary Pharmacology & Therapeutics
The team's primary outcome was therapy response, defined as hemoglobin normalization or increase ≥2 g/dL.

The research team included 5 randomized, controlled trials were included in a network meta-analysis. 

Only ferric carboxymaltose was significantly more effective than oral iron. 

Rank probabilities showed ferric carboxymaltose to be most effective, followed by iron sucrose, iron isomaltose and oral iron. 

The team found that pooled data from the systematic review revealed adverse event rates of 12%, 15%, 12%, 17% for ferric carboxymaltose, iron sucrose, iron dextran and iron isomaltose, respectively. 

The researchers noted that 1 drug-related serious adverse event each was reported for ferric carboxymaltose and iron isomaltoside, and one possibly drug-related serious adverse event for iron sucrose.

Dr Stein's team comments, "Ferric carboxymaltose was the most effective intravenous iron formulation, followed by iron sucrose."

"In addition, ferric carboxymaltose tended to be better tolerated."

"Thus, nanocolloidal IV iron products exhibit differing therapeutic and safety characteristics and are not interchangeable."

Aliment Pharmacol Ther 2017: 45(10): 1303–1318
26 April 2017

Go to top of page Email this page Email this page to a colleague

 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Preventing hepatic encephalopathy-related readmissions
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure
 05 December 2017 
Childhood obesity into adulthood
 05 December 2017 
CT imaging for acute diverticulitis
 05 December 2017 
Thiopurines and colorectal cancer in IBD
 04 December 2017 
Neoadjuvant chemoradiation for locally advanced rectal cancer
 04 December 2017 
Physical activity and Barrett’s esophagus
 04 December 2017 
Alcohol abstinence and alcoholic hepatitis
 01 December 2017 
Therapeutic drug monitoring in IBD
 01 December 2017 
Insulin therapy and liver cancer among diabetics
 01 December 2017 
Family burden of pediatric Crohn's in the USA
 30 November 2017 
Anastomotic leak after repeat intestinal resection in Crohn’s
 30 November 2017 
Oral capsule– vs colonoscopy-delivered fecal microbiota transplant
 30 November 2017 
Sessile serrated polyps and H. pylori in the USA
 29 November 2017 
Medical cannabinoid legalization policy and vomiting
 29 November 2017 
Predicting mortality after colectomy for C. diff
 29 November 2017 
Obesity and cancer risk
 28 November 2017 
Celiac disease screening in adult first-degree relatives
 28 November 2017 
Electronic health record alert in primary care in Hep C
 28 November 2017 
Surgical treatment delays and colon cancer survival
 27 November 2017 
Challenges in measuring the affordability of US health care
 27 November 2017 
Questionnaire fore chronic constipation
 27 November 2017 
Early readmission in IBD patients
 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Predicting microscopic colitis
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us